Implementation of guidelines for metabolic syndrome control in kidney transplant recipients: results at a single center

Table 1 Patient characteristics

	1994–1997	2008–2011	p value
Number of patients	74	238
Sex			0.489^a
Male	66.20 %	61.80 %
Female	33.80 %	38.20 %
ESRD etiology			<0.005^b
APCKD	4.84 %	12.44 %
Familial	11.29 %	15.79 %
Glomerular disease	53.23 %	37.32 %
DM	3.23 %	12.44 %
HTN	0.00 %	5.26 %
Other	27.42 %	16.75 %
Creatinine at beginning of FU period (μmol/l) (mean)	134	128	0.314^c
Weight at beginning of FU period (kg) (mean)	72.3	78	0.01^c
Pre-transplant DM	2.8 %	16.9 %	0.002^a
Cyclosporine treatment	90.5 %	29.0 %	<0.001^a
Last cyclosporine level (ng/mL) (mean)	139.3	63.3	<0.0001^c
Tacrolimus treatment	0.0 %	60.9 %	<0.001^a
Last tacrolimus level (ng/mL) (mean)	–	5.5
Place of transplant			<0.001^a
Israel	80.0 %	47.8 %
USA/Europe	6.7 %	11.4 %
Others	13.3 %	40.8 %
Donor living/deceased			0.002^a
Deceased	50.8 %	29.6 %
Living	49.2 %	70.4 %
Donor related	31.0 %	29.9 %	0.868^a
Age at beginning of FU (mean)	43.15 ± 11.3	49.69 ± 13.6	0.001^c
Years on dialysis (mean)	4.13 ± 4.9	2.88 ± 3.5	0.076^c
Age at transplantation (mean)	38.57 ± 11.8	42.29 ± 14.4	0.026^c
Years from transplantation (mean)	4.84 ± 3.8	7.15 ± 5.0	0.001^c

ADPKD adult polycystic kidney disease, DM diabetes mellitus, HTN hypertension, FU follow up
^aPearson Chi square
^bFisher’s exact test
^cT-test

ISSN: 1758-5996